Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pacira to raise $63m more as Exparel reaches the market and seeks new indication

This article was originally published in Scrip

Executive Summary

The US specialty pharmaceutical company Pacira Pharmaceuticals has launched the analgesic formulation Exparel (bupivacaine liposome injectable suspension), and priced a common stock offering at $9.75 per share to raise up to $62.9 million in net proceeds, all in the space of a week.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC016974

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel